Exocrine pancreatic insufficiency and hyperoxaluria: a preventable renal complication from gastroenterology
DOI:
https://doi.org/10.47892/rgp.2026.461.2078Keywords:
Exocrine Pancreatic Insufficiency, Hyperoxaluria, Kidney Diseases, OxalatesAbstract
Exocrine pancreatic insufficiency (EPI) is the inability of the pancreas to produce essential digestive enzymes for fat metabolism, leading to systemic and nutritional repercussions. Although its manifestations are typically digestive, systemic complications such as enteric hyperoxaluria can occur. We present a 68-year-old man with insulin-dependent diabetes mellitus, who developed steatorrheic diarrhea and significant weight loss. Computed tomography revealed an atrophic pancreas with diffuse calcifications. Based on a diagnosis of chronic pancreatitis, pancreatic enzyme replacement therapy (PERT) was initiated empirically with clinical improvement. Three years later, while asymptomatic from a gastrointestinal perspective, he developed bilateral calcium oxalate nephrolithiasis progressing to end-stage renal disease, requiring hemodialysis. This was interpreted as oxalate nephropathy secondary to enteric hyperoxaluria, favored by suboptimal PERT dosing and poor follow-up adherence. PERT was optimized to 40,000 units per meal with good nutritional and digestive outcomes. The etiological study for EPI showed no obstructive or systemic causes. This case highlights the importance of suspecting EPI when systemic complications like secondary hyperoxaluria appear. Early diagnosis remains challenging and requires close monitoring, as specific guidelines to prevent irreversible renal damage are lacking; early recognition can significantly improve prognosis and quality of life.
Downloads
Metrics
References
Whitcomb DC, Buchner AM, Forsmark CE. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. Gastroenterology. 2023;165(5):1292-301. doi: 10.1053/j.gastro.2023.07.007.
Lewis D. An Updated Review of Exocrine Pancreatic Insufficiency Prevalence finds EPI to be More Common in General Population than Rates of Co-Conditions. J Gastrointestin Liver Dis. 2024;33(1):123-30. doi: 10.15403/jgld-5005.
Capurso G, Traini M, Piciucchi M, Signoretti M, Arcidiacono PG. Exocrine pancreatic insufficiency: Prevalence, diagnosis, and management. Clin Exp Gastroenterol. 2019;12:129-139. doi: 10.2147/CEG.S168266.
Hwang HJ, Petruzzi ML, Gutiérrez S, Fuxman C, Nachman F. La insuficiencia pancreática exocrina: estado actual de su conocimiento entre los profesionales de Argentina. Acta Gastroenterol Latinoam. 2020;50(4):431-8.
Chen T, Qian B, Zou J, Luo P, Zou J, Li W, et al. Oxalate as a potent promoter of kidney stone formation. Front Med (Lausanne). 2023;10:1159616. doi: 10.3389/fmed.2023.1159616.
Demoulin N, Issa Z, Crott R, Morelle J, Danse E, Wallemacq P, et al. Enteric hyperoxaluria in chronic pancreatitis. Medicine (Baltimore). 2017;96(19):e6758. doi: 10.1097/ MD.0000000000006758.
Baltazar P, de Melo Junior AF, Fonseca NM, Lança MB, Faria A, Sequeira CO, et al. Oxalate (dys)Metabolism: Person-to-Person Variability, Kidney and Cardiometabolic Toxicity. Genes (Basel). 2023;14(9):1719. doi: 10.3390/genes14091719.
Dominguez-Muñoz JE, Vujasinovic M, de la Iglesia D, Cahen D, Capurso G, Gubergrits N, et al. European guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency: UEG, EPC, EDS, ESPEN, ESPGHAN, ESDO, and ESPCG evidencebased recommendations. United European Gastroenterol J. 2025;13(1):125-72. doi: 10.1002/ueg2.12674.
Buysschaert B, Aydin S, Morelle J, Gillion V, Jadoul M, Demoulin N. Etiologies, Clinical Features, and Outcome of Oxalate Nephropathy. Kidney Int Rep. 2020;5(9):1503-1509. doi: 10.1016/j.ekir.2020.06.021.
Tilia R, Kojc N, Škoberne A. Secondary oxalate nephropathy in a patient with exocrine pancreatic insufficiency successfully treated, with complete kidney recovery. Clin Nephrol. 2021;96(1):62-67. doi: 10.5414/CNP96S11.
Domínguez-Muñoz JE. Pancreatic exocrine insufficiency: Diagnosis and treatment. J Gastroenterol Hepatol. 2011;26(s2):12-6. doi: 10.1111/j.1440-1746.2010.06600.x.
De Martines D, Gianotten S, Wetzels J, Van der Meijden W. Secondary hyperoxaluria due to pancreatic insufficiency. Neth J Med. 2019;77(08):287-92.
Roodnat JI, de Mik-van Egmond AME, Visser WJ, Berger SP, van der Meijden WAG, Knauf F, et al. A Successful Approach to Kidney Transplantation in Patients With Enteric (Secondary) Hyperoxaluria. Transplant Direct. 2017;3(12):e331. doi: 10.1097/TXD.0000000000000748.
Quintero E, Bird VY, Liu H, Stevens G, Ryan AS, Buzzerd S, et al. A Prospective, Double-Blind, Randomized, PlaceboControlled, Crossover Study Using an Orally Administered Oxalate Decarboxylase (OxDC). Kidney360. 2020;1(11):1284- 1290. doi: 10.34067/KID.0001522020.
Liu H feng, Li C yan, Liu Y hong, Yao Q, Li Q shan, Yu LJ. OxDc-A0: an oral gastro-tolerant oxalate decarboxylase for treating secondary hyperoxaluria. Urolithiasis. 2025;53(1):47. doi: 10.1007/s00240-025-01698-0.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ernesto Hornung, Ignacio Moratorio, Serena Amor, Mariana Seija, Adrián Canavesi

This work is licensed under a Creative Commons Attribution 4.0 International License.
Revista de Gastroenterología del Perú by Sociedad Peruana de Gastroenterología del Perú is licensed under a Licencia Creative Commons Atribución 4.0 Internacional..
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).











2022